# Bain Capital Life Sciences

> Bain Capital Life Sciences invests in biotechnology, pharmaceuticals, medical devices, diagnostics and life-science tools. It co-led OMass Therapeutics’ $310M Series C announced on October 15, 2026, alongside Forbion and Novo Holdings. It is distinct from Bain Capital Ventures.

## Profile

- **Stage-based planning range:** $100K–$1M
- **Check-size evidence basis:** estimated
- **Founded:** N/A
- **Headquarters:** Boston, United States
- **AUM:** N/A
- **Rounds they lead:** Series C
- **Rounds they invest:** N/A
- **Last verified:** 2026-10-15T17:10:38Z

## Links

- [Website](https://www.baincapitallifesciences.com/)

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** October 15, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/fund/bain-capital-life-sciences